{"filings":[{"id":94938,"accession_number":"0001493152-26-018562","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vivos Therapeutics gets Nasdaq delisting notice for negative equity of $1.55M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Negative stockholders' equity of ~$1.55M as of Dec 31, 2025, below Nasdaq's $2.5M minimum requirement.","Nasdaq letter received April 17, 2026; Company must submit compliance plan by June 1, 2026.","Raised $6.8M in Q1 2026: $4.6M warrant exercise inducement + $2.25M private placement with existing investor.","If plan accepted, Nasdaq may grant extension to Oct 14, 2026; failure to regain compliance risks delisting.","No immediate impact on common stock listing; Company intends to submit plan timely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94937,"accession_number":"0001493152-26-016865","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Therapeutics FY2025 revenue up 16% to $17.5M; operating loss widens to $19.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $17.5M, +16% YoY from $15.0M; driven by sleep testing services and SCN acquisition.","Operating loss $19.9M vs $11.2M in FY2024; expenses rose to $30.4M on SCN integration costs.","Cash and equivalents $2.0M at Dec. 31, 2025; subsequent financing raised $6.8M in gross proceeds.","Gross margin held at 60%; business pivoting from VIP enrollment to sleep provider acquisitions and alliances.","Management targets achieving cash-flow-positive operations by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94936,"accession_number":"0001493152-26-015132","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vivos Therapeutics raises ~$2.39M in PIPE financing from V-Co 3; includes conversion of $1.4M bridge note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,353,625 shares, pre-funded warrant for 429,957 shares, and Series A/B warrants for 1,783,582 each at $1.34 per unit.","Cash proceeds of $850,000; $1,400,000 bridge note converted; gross proceeds $2,390,000.","Series A/B warrants exercisable at $1.09 (2 and 5 year terms); pre-funded warrant exercisable at $0.0001.","Company must file resale registration statement within 45 days and use best efforts for effectiveness within 90 days.","Net proceeds to be used for general working capital purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107672,"accession_number":"0001493152-26-005554","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vivos Therapeutics appoints Gregg C. E. Johnson as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregg C. E. Johnson appointed independent director effective Feb 4, 2026; will serve on Compensation Committee.","Annual cash fee of $48,000 plus $5,000 per committee membership; eligible for stock options under 2024 Equity Incentive Plan.","Johnson previously served as Secretary (2016-2020) and director (2016-2018) of Vivos; has law degree and experience in emerging companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107671,"accession_number":"0001493152-26-002844","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vivos Therapeutics raises $4.6M via warrant exercise and issues new warrants for 3.96M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.6M from immediate cash exercise of existing warrants at reduced price of $2.34/share.","Issued Series A (5-yr) and Series B (24-mo) warrants to purchase up to 3,964,712 shares at $2.09/share.","Must file resale registration for new warrant shares by Feb 14, 2026; effective by Mar 16 or Apr 15 if SEC review.","Placement agent H.C. Wainwright paid 7% cash fee and received warrants for 138,765 shares at $2.925/share.","Until Feb 19, 2026, company restricted from issuing additional shares or filing registration statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107670,"accession_number":"0001493152-26-002557","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Vivos Therapeutics enters $5.5M convertible note with V-Co, initial $900k funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Note up to $5.5M principal (incl. 10% OID) from V-Co Investors 3 LLC, affiliate of existing investor New Seneca Partners.","Initial $900k funded; additional advances possible until Feb 16, 2026 outside date for proposed equity financing.","Principal converts dollar-for-dollar into equity instruments of proposed Subsequent Financing; no interest unless default (then 15%).","Company expects to close $5.5M equity financing by Feb 16, 2026; note supports that process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124044,"accession_number":"0001493152-25-028019","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos Therapeutics opens affiliated sleep center in Auburn Hills, Michigan under MISleep Solutions agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grand opening of sleep testing and treatment center near Detroit in Auburn Hills, MI on Dec 16, 2025.","Center operates under July 2025 agreement with MISleep Solutions, LLC for management/support services.","Model is capital-efficient contractual alliance, distinct from outright acquisition; follows summer 2025 acquisition of The Sleep Center of Nevada.","Vivos brings FDA-cleared diagnostic and therapeutic products for obstructive sleep apnea (OSA) to the center.","Company is in talks with other sleep center groups across the U.S. for similar affiliations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124043,"accession_number":"0001493152-25-026438","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Vivos Therapeutics issues $2.09M unsecured note, net proceeds $1.5M, weekly $70K payments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $2,093,340; net proceeds ~$1,500,000 after $587,340 OID and $6,000 fees.","Weekly payments of $69,778 start December 12, 2025; full prepay by Jan 4, 2026 reduces balance by $286,140.","Note is unsecured, no interest unless default; subsidiary Airway Integrated Management guarantees obligations.","Proceeds for working capital and general corporate purposes; no placement agent used.","Lender Avondale Capital is affiliate of Streeterville Capital (prior senior secured loan from June 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124042,"accession_number":"0001493152-25-024289","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Q3 revenue $6.8M (+78% seq, +76% YoY); operating loss widens to $4.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $6.8M in Q3 2025, driven by first full quarter of Sleep Center of Nevada (SCN) acquisition; SCN added $2.2M diagnostic and $1.3M treatment revenue.","Gross profit $3.9M (58% margin, down from 60% YoY); operating expenses $8.7M (+74% YoY) on SCN-related headcount and depreciation.","Operating loss $4.7M ($2.6M in Q3 2024); cash $3.1M at Sept 30, 2025 vs $6.3M at Dec 31, 2024.","Entered management agreement with MISleep Solutions for a joint location in Auburn Hills, MI, seeing patients from December; owns supermajority equity.","Conference call at 5:00 pm ET; replay available until Dec 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":13619000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124041,"accession_number":"0001493152-25-020750","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vivos Therapeutics 2025 annual meeting elects directors, approves equity plan amendment, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Huntsman, Green, Krammer, Lindsay, Sokolow, Thompson; each with >2.6M votes for.","Amendment to 2024 Omnibus Equity Incentive Plan approved with 2.45M for, 516K against, 2.3K abstain.","Appointment of Baker Tilly US, LLP as auditor for FY ending Dec 31, 2025 ratified with 4.86M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124040,"accession_number":"0001493152-25-019359","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos Therapeutics expands at-the-market equity offering under existing agreement","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Filed prospectus supplement to increase aggregate offering price of common stock under ATM agreement with H.C. Wainwright & Co. (dated Feb 14, 2025).","No specific increase amount or prior cap disclosed in the 8-K filing.","Legal opinion on share issuance attached as Exhibit 5.1; no other material changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140717,"accession_number":"0001493152-25-013953","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos DNA appliance shows 77% of pediatric OSA patients achieve ≥50% severity reduction in peer-reviewed trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["77% of participants had ≥50% reduction in OSA severity; 93% with severe OSA reached that threshold.","17% of children achieved complete resolution of OSA; airway volume increased 67.8% on average.","Pediatric Sleep Questionnaire scores improved 31% – statistically significant.","Data published in European Journal of Pediatrics; first multicenter trial for DNA appliance in pediatric OSA.","Study provides evidence for non-surgical alternative to adenotonsillectomy, which is only 20–40% effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140716,"accession_number":"0001641172-25-027210","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos Therapeutics files prospectus supplement for up to $5.83M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $5,830,572 of common stock through H.C. Wainwright as sales agent.","No shares had been sold under prior ATM agreement as of September 12, 2025.","Shelf registration statement S-3 (333-284834) declared effective by SEC on September 10, 2025.","Common stock par value $0.0001 per share; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140714,"accession_number":"0001641172-25-025396","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K/A","filed_at":"2025-08-25T23:59:59+00:00","items":["9.01","1.01","2.01","8.01"],"status":"ready","headline":"Vivos closes Sleep Center of Nevada acquisition for $6M cash + stock; issues $8.25M note","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired operating assets of SCN for $6M cash, 607k restricted shares ($1.5M at VWAP), plus contingent earn-out of up to $1.5M in stock.","Wholly-owned AIM subsidiary signed 15-year PAAs with SCN ($200k/mo fee) and SCN PLLC ($100k/mo fee) to manage practice in compliance with CPM laws.","Issued $8.25M secured promissory note to Streeterville Capital to finance the acquisition; AIM membership interests pledged as collateral.","Integration of two of seven SCN locations underway; deploying 1.5 SO teams currently, targeting 4.5 teams by Q1 2026; patient demand exceeds capacity.","SCN revenue expected in Q2 fiscal 2025; risk factors note unproven model, CPM law compliance, and debt service obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140715,"accession_number":"0001641172-25-024979","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Therapeutics reports Q2 2025 revenue $3.8M, operating loss $4.9M; acquired Sleep Center of Nevada","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $3.8M vs $4.1M YoY; gross margin fell to 55% from 65%.","Operating loss widened to $4.9M from $1.9M; expenses up 52% on acquisition-related costs.","Cash at June 30, 2025 was $4.4M, down from $6.2M at December 31, 2024.","Acquired Sleep Center of Nevada on June 10; generated ~$500k diagnostic revenue in 20 days with demand exceeding capacity.","Entered management agreement with MISleep Solutions for Michigan center; opening expected October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":6835000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158446,"accession_number":"0001641172-25-015115","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Vivos closes $6M+stock acquisition of Sleep Center of Nevada; secures $11M+ financing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired SCN for $6M cash + $1.5M in stock (607,287 shares) + assumption of liabilities; up to $1.5M earn-out in stock.","Senior secured loan of $8.25M from Streeterville Capital (9% interest, 18-month maturity) netted $7.5M to Vivos.","PIPE from New Seneca affiliate: 828K shares, pre-funded warrant for 725K shares, and 5-yr warrant for 2.33M shares at $2.23; total gross ~$3.755M.","SCN sees ~3,000 new patients/month, annual high-seven-figure revenue; 90% test positive for OSA; Vivos expects to add diagnostic/appliance revenue over 12-18 months.","Board-certified sleep specialists Dr. Prabhu Rachakonda and Dr. Tara Rachakonda join Vivos; continue practice management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158445,"accession_number":"0001641172-25-014118","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Vivos Therapeutics appoints Baker Tilly as independent auditor after Moss Adams merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Moss Adams merged into Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.","Audit committee approved Baker Tilly as successor independent registered public accounting firm.","No disagreements or reportable events between Vivos and Moss Adams during 2023, 2024, or through June 3, 2025.","Moss Adams' prior audit reports contained an explanatory paragraph regarding going concern uncertainty.","No consultations with Baker Tilly on accounting principles or disagreements occurred before appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158444,"accession_number":"0001641172-25-012181","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Vivos Therapeutics enters $1.1M convertible note to fund pending SCN acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.1M principal convertible note to V-Co Investors 2 LLC; net funding $1M after $100k fee.","Zero interest unless default; default rate 15% p.a.; secured by equipment only on default.","Converts automatically into equity of subsequent financing expected at SCN closing (target July 31, 2025).","Proceeds to fund previously announced acquisition of The Sleep Center of Nevada.","V-Co is affiliate of existing investor New Seneca Partners Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158443,"accession_number":"0001641172-25-011084","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Q1 2025 product rev +8% YoY, net loss $3.9M; acquires Sleep Center of Nevada for up to $9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.0M (-12% YoY) as pivot away from VIP service revenue; product revenue up 8% to $1.8M from appliance arch sales.","Net loss $3.9M (+3% YoY); operating expenses $5.4M (-5% YoY) reflecting cost-cutting.","Cash $2.3M, equity $4.4M at March 31, 2025.","Entered definitive agreement on April 15, 2025 to acquire The Sleep Center of Nevada for up to $9M cash/stock; expected close within two months.","Sold 3,736 oral appliance arches (vs 1,996 in Q1 2024) driving product revenue increase."],"consensus_eps_estimate":-0.408,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":3016000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158442,"accession_number":"0001641172-25-005165","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vivos Therapeutics signs $9M deal to acquire Nevada sleep center operator SCN","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $9M: $6M cash + $1.5M stock at closing + $1.5M stock earn-out.","SCN sees ~3,000 new patients/month; annual revenue in high seven figures; 7 locations in Nevada.","Close expected Q2/Q3 2025, subject to financing, audit, and customary conditions; no shareholder vote needed.","Employment agreement for Dr. Rachakonda includes $400K salary and board observation right; New Seneca Partners assisted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176813,"accession_number":"0001641172-25-001895","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Therapeutics reports FY2024 revenue up 9% to $15M; operating loss narrows 35%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.0M (+9% YoY); product revenue increased 26%; gross profit $9.0M at 60% margin.","Operating loss reduced 35% to $11.2M from $17.3M; operating expenses down 21%.","Cash $6.3M; raised $17.9M via four equity transactions including $7.5M from New Seneca Partners.","FDA 510(k) clearance for DNA appliance to treat moderate-to-severe OSA in children ages 6-17.","New strategic alliance with Rebis Health; expects 4-6x increase in revenue per case under new distribution model."],"consensus_eps_estimate":-0.408,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":3016000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176812,"accession_number":"0001493152-25-006584","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Vivos Therapeutics enters $3.3M ATM equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed ATM offering agreement to sell up to $3,328,881 of common stock through H.C. Wainwright.","Wainwright will receive a 3% cash commission on gross sales proceeds as agent.","Offering terminates upon sale of all shares or earlier termination by either party.","Amended employment agreements for CEO Huntsman and CFO Amman effective Jan 1, 2025 (previously reported)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193624,"accession_number":"0001493152-24-051890","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Vivos Therapeutics announces $3.5M registered direct offering of 709,220 shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.5M from 709,220 shares at $4.935 each; warrants exercisable at $4.81 for two years.","Additional ~$3.4M if warrants fully exercised; net proceeds for working capital and general corporate purposes.","H.C. Wainwright receives 7% cash fee, 1% management fee, and placement agent warrants for 49,645 shares at $6.1688.","Closing expected Dec 24, 2024; 45-day lock-up on share issuance and one-year restriction on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193623,"accession_number":"0001493152-24-048065","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vivos stockholders elect all director nominees and approve 2024 equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six directors elected: Huntsman, Green, Krammer, Lindsay, Sokolow, Thompson; each received ~1.1M for, ~155-193K withheld.","2024 Omnibus Equity Incentive Plan approved with 957,268 for, 313,560 against, 17,747 abstentions.","Ratification of Moss Adams LLP as auditor for FY2024 passed with 2,496,723 for, 162,219 against, 35,623 abstentions.","Approximately 2.7M of 4.8M outstanding shares voted, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193622,"accession_number":"0001493152-24-045904","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Therapeutics Q3 revenue up 17% to $3.9M; operating loss down 27%; FDA clearance for pediatric OSA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $3.9M (+17% YoY); gross margin improved to 60% from 53%.","Operating loss decreased $1M (27%) YoY; operating expenses down 8% — ninth consecutive quarter of reduction.","Cash and equivalents $6.3M, stockholders' equity $7.7M; raised $4.3M via registered direct equity offering in Sept.","First FDA 510(k) clearance for treating moderate-to-severe OSA in children 6-17; AMA CPT codes for Vivos devices effective Jan 1, 2025.","Over 47,000 patients treated globally; new marketing model expanding to two more Colorado locations by early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":11333000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209928,"accession_number":"0001493152-24-037254","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Vivos Therapeutics prices $4.3M registered direct offering of 1,363,812 shares at $3.15/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.3M before fees; closing expected Sept 20, 2024.","Placement agent H.C. Wainwright receives 7% cash fee plus 95,467 warrants at $3.9375.","Net proceeds to be used for working capital and general corporate purposes.","No warrants issued to investors; offering priced at-the-market under Nasdaq rules.","Shares sold under effective shelf registration statement (File No. 333-262554)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209927,"accession_number":"0001493152-24-036942","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivos Therapeutics receives first FDA 510(k) clearance for oral device to treat pediatric OSA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Vivos' DNA appliance to treat moderate to severe OSA and snoring in children aged 6–17.","Up to 10.1 million U.S. children estimated to suffer from pediatric OSA; current standard is adenotonsillectomy.","Clinical study (n=48) showed 62.7% improvement in AHI, 58% snoring reduction, no safety concerns.","Company plans to leverage clearance via new marketing & distribution alliances with medical sleep providers.","Believed to be first-ever FDA clearance of an oral medical device for pediatric OSA treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209926,"accession_number":"0001493152-24-036852","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Vivos Therapeutics sets 2024 Annual Meeting for Nov 26; Oct 4 record date; Sep 27 deadline for proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Annual Meeting scheduled for Tuesday, November 26, 2024.","Record date for voting set at close of business on October 4, 2024.","Stockholder proposals under Rule 14a-8 must be received by September 27, 2024.","Director nominations and non-proxy proposals also due by September 27, 2024.","Address for submissions: Corporate Secretary, Vivos Therapeutics, Inc., 7921 Southpark Plaza, Suite 210, Littleton, CO 80120."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209925,"accession_number":"0001493152-24-036065","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vivos Therapeutics approves new equity plan and amended CEO/CFO employment deals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2024 Omnibus Plan (subject to stockholder vote) with 1,600,000 shares available for future awards.","Contingent option grants: CEO Huntsman 315,421 ISOs, CFO Amman 149,533 ISOs at $2.62/share, 3-year vesting.","Amended employment agreements effective Jan 1, 2025 raise CEO base salary to $450,000 and CFO to $320,000.","Severance: 12-month salary continuation on non-cause termination; 24 months after change-in-control; full equity vesting.","New plan will replace 2019 Plan; unused shares retired if stockholders approve at 2024 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209924,"accession_number":"0001493152-24-032453","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Therapeutics Q2 revenue up 19% YoY to $4.1M; operating expenses down 31%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M vs $3.4M YoY; gross margin improved to 65% from 62%.","Operating loss reduced 57% YoY; eight straight quarters of YoY expense cuts.","Cash $6.9M; stockholders' equity $6.3M; expects positive cash flow in early 2025.","Received Medicare reimbursement for CARE oral devices; closed $7.5M equity investment from New Seneca Partners.","New strategic alliance with sleep testing centers in Colorado; pilot showed 79% of patients chose Vivos therapy over CPAP."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":7473000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209923,"accession_number":"0001493152-24-026723","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq panel grants Vivos continued listing subject to filing Q2 Form 10-Q by Aug 15, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Panel granted continued listing on Nasdaq conditional on filing Form 10-Q for quarter ended June 30, 2024 by August 15, 2024.","Company must evidence stockholders' equity of at least $2.5 million in the Form 10-Q.","Exploring additional equity financing to maintain compliance with Nasdaq equity requirement.","Risk of delisting if compliance not achieved; delisting would materially harm stock price and capital access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228129,"accession_number":"0001493152-24-025102","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vivos Therapeutics updates Nasdaq compliance status after $7.5M private placement; hearing June 27","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on May 16, 2024 for failing to meet $2.5M equity requirement.","Completed $7.5M private placement on June 10, 2024; believes it now meets equity requirement.","Hearing before Nasdaq Panel scheduled June 27, 2024; decision expected within 30 days.","Company acknowledges it will need additional equity capital to maintain ongoing compliance.","Risk of delisting if unable to demonstrate compliance; could materially affect stock price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228128,"accession_number":"0001493152-24-023871","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vivos closes $7.5M private placement with Seneca; launches strategic alliance for sleep apnea treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $7.5M from sale of 3,220,266 shares/pre-funded warrants and 5-year warrants at $2.329/share to Seneca affiliate V-CO.","Strategic alliance with Rebis Health (Colorado) to jointly offer CPAP and Vivos' oral appliances at two centers starting July 2024; revenue-sharing model.","Seneca receives board observation rights and a management services fee of $37,500/quarter; cash participation in alliance net cash flow.","Company intends to use proceeds for working capital; must file resale registration by July 25, 2024.","Management expects new model to reduce cash burn, improve gross profit per case, and drive revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228127,"accession_number":"0001493152-24-020446","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vivos Therapeutics receives Nasdaq delisting notice for failing minimum equity requirement again","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On May 16, 2024, Nasdaq notified Vivos that stockholders' equity fell below $2.5M as of March 31, 2024.","Company previously regained compliance on May 6, 2024, but new Q1 10-Q filing shows equity < $2.5M.","Company has filed appeal; delisting is stayed pending Hearing Panel decision.","If delisted, material adverse effect on stock price, liquidity, capital raising, and reputation.","No assurance the company can regain or maintain compliance with the minimum equity requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228126,"accession_number":"0001493152-24-019739","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Q1 revenue down 10.5% to $3.4M, operating expenses cut 22%; Medicare reimbursement approved for CARE devices","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $3.4M vs $3.8M YoY; gross margin 57% vs 61%.","Operating expenses down 22% YoY ($1.6M reduction); operating loss reduced 24% YoY.","Cash $2.6M at March 31; Feb 2024 warrant exercise raised ~$4.0M from 980,393 shares.","April 2024: received Medicare reimbursement approval for CARE oral devices, enabling coverage for beneficiaries.","Management targets cash flow positive from operations by end of 2024 or Q1 2025, assuming revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":3419000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228125,"accession_number":"0001493152-24-017782","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vivos awaits Nasdaq confirmation on equity compliance; warns of delisting risk if capital insufficient","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company believes it met $2.5M minimum equity requirement by March 19, 2024, via capital raises in Nov 2023 and Feb 2024.","Nasdaq has not yet confirmed compliance; will monitor ongoing compliance at next periodic report.","Company expects to need additional equity capital to maintain compliance; failure could lead to delisting.","Delisting would materially harm stock price, liquidity, capital raising ability, and reputation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246897,"accession_number":"0001493152-24-011834","cik":1716166,"company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivos Therapeutics Reports FY2023 Revenue Decline, 27% OpEx Reduction, and FDA Clearance for Severe OSA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for Q4 2023 was $3.2M and full year $13.8M, down from $4.0M and $16.0M in 2022, due to lower appliance revenue and VIP enrollments.","Operating expenses decreased 27% in FY2023, leading to a 43% reduction in net loss, as cost-cutting initiatives took effect.","In November 2023, Vivos received FDA 510(k) clearance for its CARE oral appliances to treat severe OSA in adults, a first for oral devices.","Signed VIP enrollment contracts increased 38% sequentially in Q4 2023 following the FDA clearance, indicating improved business momentum.","Cash and equivalents were $1.6M at year-end; a warrant exercise in February 2024 generated $4.0M in gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}